DeAnna Diaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
DeAnna Diaz has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Victoria P. Werth
Corporal Michael J. Crescenz Veterans Affairs Medical Center Philadelphia, Philadelphia, Pennsylvania, USA; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
9 shared publications - Thomas Vazquez
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA
7 shared publications - Madison Grinnell
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
6 shared publications - Emily Keyes
Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania, USA; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
4 shared publications - Muhammad M. Bashir
Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania, USA; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
4 shared publications - Nilesh Kodali
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA 19104, USA
3 shared publications
Latest Publications
- 15 January 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (7) , 1827-1836.e4
Lenabasum, a cannabinoid type 2 receptor agonist, exerts anti-inflammatory effects in dermatomyositis
- 15 January 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (7) , 1827-1836.e4
Lenabasum, a cannabinoid type 2 receptor agonist, exerts anti-inflammatory effects in dermatomyositis
- 30 December 2025
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 48 (3) , 250-253
Verocay and Verocay-Like Bodies: Is There a Distinction? Spindle Cell Lipoma as an Example
Spindle cell lipoma (SCL) is a benign adipocytic tumor commonly occurring in the neck, back, and shoulder of middle-aged men. Although often straightforward, SCL can exhibit unusual histologic patterns that pose diagnostic challenges. Verocay bodies, characterized by palisading nuclei around acellular zones, are a classic feature of schwannoma but are not pathognomonic. We report a SCL on the posterolateral neck of a 48-year-old man that showed prominent palisaded arrangements reminiscent of Verocay bodies, prompting a differential that included schwannoma. Immunohistochemical studies were performed, and the spindle cells were negative for S100 (only scattered adipocytes highlighted), and positive for CD34, and showed loss of nuclear RB staining. These findings are characteristic of SCL and the case underscores the importance of integrating microscopy, immunohistochemical panel selection, and terminology discipline. Recognizing the pitfalls of indiscriminate “Verocay-like body” nomenclature in nonschwannomatous neoplasms is crucial for avoiding misdiagnosis.
- 30 December 2025
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 48 (3) , 250-253
Verocay and Verocay-Like Bodies: Is There a Distinction? Spindle Cell Lipoma as an Example
Spindle cell lipoma (SCL) is a benign adipocytic tumor commonly occurring in the neck, back, and shoulder of middle-aged men. Although often straightforward, SCL can exhibit unusual histologic patterns that pose diagnostic challenges. Verocay bodies, characterized by palisading nuclei around acellular zones, are a classic feature of schwannoma but are not pathognomonic. We report a SCL on the posterolateral neck of a 48-year-old man that showed prominent palisaded arrangements reminiscent of Verocay bodies, prompting a differential that included schwannoma. Immunohistochemical studies were performed, and the spindle cells were negative for S100 (only scattered adipocytes highlighted), and positive for CD34, and showed loss of nuclear RB staining. These findings are characteristic of SCL and the case underscores the importance of integrating microscopy, immunohistochemical panel selection, and terminology discipline. Recognizing the pitfalls of indiscriminate “Verocay-like body” nomenclature in nonschwannomatous neoplasms is crucial for avoiding misdiagnosis.
- 12 September 2025
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (10) , e70045
DICER1 mutations in Bethesda III/IV thyroid cytology samples: A multicenter observational study
Background: Mutations in DICER1 are uncommon, poorly understood, and infrequently found in thyroid nodules.Methods: The objective of this study was to investigate category III/IV thyroid nodules according to The Bethesda System for Reporting Thyroid Cytopathology with DICER1 gene mutations detected in fine‐needle aspiration cytology samples using ThyroSeq v3 molecular testing, with a focus on an exploration of the clinical and histopathologic outcomes of these nodules. In this multicenter study spanning more than 6 years, nodules were retrospectively analyzed for patient demographics, clinical course, cytologic features, and histopathology, where available.Results: In total, 88 patients with somatic DICER1 mutations were included, with a mean age of 39.6 years and a female predominance. All mutations were in the somatic hotspot region, most commonly at the codon 5437 site. Most excised nodules showed benign histologic features (65.9%). Interestingly, the rate of malignancy was higher in this cohort compared with that in the national average.Conclusions: DICER1 mutations appear to confer a higher risk of malignancy, but are not associated with any specific cytological or histopathological distinguishing features.
- 12 September 2025
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (10) , e70045
DICER1 mutations in Bethesda III/IV thyroid cytology samples: A multicenter observational study
Background: Mutations in DICER1 are uncommon, poorly understood, and infrequently found in thyroid nodules.Methods: The objective of this study was to investigate category III/IV thyroid nodules according to The Bethesda System for Reporting Thyroid Cytopathology with DICER1 gene mutations detected in fine‐needle aspiration cytology samples using ThyroSeq v3 molecular testing, with a focus on an exploration of the clinical and histopathologic outcomes of these nodules. In this multicenter study spanning more than 6 years, nodules were retrospectively analyzed for patient demographics, clinical course, cytologic features, and histopathology, where available.Results: In total, 88 patients with somatic DICER1 mutations were included, with a mean age of 39.6 years and a female predominance. All mutations were in the somatic hotspot region, most commonly at the codon 5437 site. Most excised nodules showed benign histologic features (65.9%). Interestingly, the rate of malignancy was higher in this cohort compared with that in the national average.Conclusions: DICER1 mutations appear to confer a higher risk of malignancy, but are not associated with any specific cytological or histopathological distinguishing features.
- 14 October 2024
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (1)
Atypical presentation of primary lung abscess in an infant
- 14 October 2024
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (1)
Atypical presentation of primary lung abscess in an infant
- Open Access
- 30 September 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-13
Keratinocyte derived extracellular vesicles mediated crosstalk between epidermis and dermis in UVB-induced skin inflammation
Background and rationale: Ultraviolet-B (UVB) light induces dermal inflammation, although it is mostly absorbed in the epidermis. Recent reports suggest extracellular vesicles (EVs) act as a mediator of photodamage signaling. Melatonin is reported to be a protective factor against UV-induced damage. We hypothesized that EVs derived from UVB-irradiated keratinocytes might trigger proinflammatory responses in dermal cells and tested whether melatonin can ameliorate UVB-induced inflammation. Methods: We used UVB-irradiated HaCaT cells, primary keratinocytes and STING knock-out mice to model production of EVs under photodamaging conditions and performed immunoblotting and ELISA to measure their effect on dermal macrophages. Results: UVB-irradiated keratinocytes produce an increased number of EVs that contain higher concentrations of DNA and protein compared with controls. KC-derived EVs (KEVs) induced a STING- and inflammasome-mediated proinflammatory response in macrophages in vitro, and a pronounced inflammatory infiltrate in mouse dermis in vivo. Melatonin ameliorated KEVs inflammatory effect both in vitro and in vivo. Conclusions: This data suggests EVs are mediators in a crosstalk that takes place between keratinocytes and their neighboring cells as a result of photodamage. Further studies exploring EVs induced by damaging doses of UVB, and their impact on other cells will provide insight into photodamage and may help develop targeted therapeutic approaches.
- 30 September 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-13
Open AccessKeratinocyte derived extracellular vesicles mediated crosstalk between epidermis and dermis in UVB-induced skin inflammation
Background and rationale: Ultraviolet-B (UVB) light induces dermal inflammation, although it is mostly absorbed in the epidermis. Recent reports suggest extracellular vesicles (EVs) act as a mediator of photodamage signaling. Melatonin is reported to be a protective factor against UV-induced damage. We hypothesized that EVs derived from UVB-irradiated keratinocytes might trigger proinflammatory responses in dermal cells and tested whether melatonin can ameliorate UVB-induced inflammation. Methods: We used UVB-irradiated HaCaT cells, primary keratinocytes and STING knock-out mice to model production of EVs under photodamaging conditions and performed immunoblotting and ELISA to measure their effect on dermal macrophages. Results: UVB-irradiated keratinocytes produce an increased number of EVs that contain higher concentrations of DNA and protein compared with controls. KC-derived EVs (KEVs) induced a STING- and inflammasome-mediated proinflammatory response in macrophages in vitro, and a pronounced inflammatory infiltrate in mouse dermis in vivo. Melatonin ameliorated KEVs inflammatory effect both in vitro and in vivo. Conclusions: This data suggests EVs are mediators in a crosstalk that takes place between keratinocytes and their neighboring cells as a result of photodamage. Further studies exploring EVs induced by damaging doses of UVB, and their impact on other cells will provide insight into photodamage and may help develop targeted therapeutic approaches.
- 10 December 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (6) , 1262-1272.e7
Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 IFN in Cutaneous Lupus: An In-Depth Immunoprofile of Subacute and Discoid Lupus
- 10 December 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (6) , 1262-1272.e7
Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 IFN in Cutaneous Lupus: An In-Depth Immunoprofile of Subacute and Discoid Lupus
- Open Access
- 4 January 2022
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 24 (1) , 1-11
Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM
Background: Lenabasum is a cannabinoid type 2 receptor (CB2R) reverse agonist that demonstrates anti-inflammatory effects in vivo and in vitro in dermatomyositis (DM) and is currently being investigated for therapeutic potential. The purpose of our study is to investigate CB2R distribution as well as the effects of lenabasum in DM. Methods: Immunohistochemistry staining (IHC) was utilized to examine immune cell and cytokine production changes in lesional DM skin biopsies from lenabasum and placebo-treated patients. CB2R expression in various immune cell populations within DM skin was investigated with image mass cytometry (IMC), whereas flow cytometry elucidated CB2R expression in DM peripheral blood mononuclear cells (PBMCs) as well as cytokine production by CB2R-expressing cell populations. Results: After 12 weeks of lenabasum treatment, IHC staining showed that CD4+ T cells, CB2R, IL-31, IFN-γ, and IFN-β cytokines were downregulated. IFN-γ and IFN-β mRNA decreased in lesional DM skin but not in PBMCs. IMC findings revealed that CB2R was upregulated in DM lesional skin compared to HC skin and DM PBMCs (pp<0.05). These CB2R+ cells in the skin produce IL-31, IL-4, IFN-γ, and IFN-β. Conclusion: Our findings of differential CB2R expression based on location and cell type suggest modes by which lenabasum may exert anti-inflammatory effects in DM and highlights dendritic cells as potential therapeutic targets.
- 4 January 2022
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 24 (1) , 1-11
Open AccessCannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM
Background: Lenabasum is a cannabinoid type 2 receptor (CB2R) reverse agonist that demonstrates anti-inflammatory effects in vivo and in vitro in dermatomyositis (DM) and is currently being investigated for therapeutic potential. The purpose of our study is to investigate CB2R distribution as well as the effects of lenabasum in DM. Methods: Immunohistochemistry staining (IHC) was utilized to examine immune cell and cytokine production changes in lesional DM skin biopsies from lenabasum and placebo-treated patients. CB2R expression in various immune cell populations within DM skin was investigated with image mass cytometry (IMC), whereas flow cytometry elucidated CB2R expression in DM peripheral blood mononuclear cells (PBMCs) as well as cytokine production by CB2R-expressing cell populations. Results: After 12 weeks of lenabasum treatment, IHC staining showed that CD4+ T cells, CB2R, IL-31, IFN-γ, and IFN-β cytokines were downregulated. IFN-γ and IFN-β mRNA decreased in lesional DM skin but not in PBMCs. IMC findings revealed that CB2R was upregulated in DM lesional skin compared to HC skin and DM PBMCs (pp<0.05). These CB2R+ cells in the skin produce IL-31, IL-4, IFN-γ, and IFN-β. Conclusion: Our findings of differential CB2R expression based on location and cell type suggest modes by which lenabasum may exert anti-inflammatory effects in DM and highlights dendritic cells as potential therapeutic targets.
- Open Access
- 9 September 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (5) , 560-575
Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis
For patients with lupus erythematosus (LE) or dermatomyositis (DM), there is an urgent need to address a heightened risk of clinical events, chiefly heart attacks and strokes, caused by atherosclerotic cardiovascular disease (ASCVD). Patients with LE or DM frequently exhibit high levels of conventional risk factors for ASCVD events, particularly dyslipoproteinemia and hypertension; an amplified burden of atherosclerotic plaques; and increased age- and sex-adjusted rates of ASCVD events compared with the general population. The rate of ASCVD events exceeds what would be expected from conventional risk factors, suggesting that disease-specific autoimmune processes exacerbate specific, known pathogenic steps in atherosclerosis. Importantly, despite their heightened risk, patients with LE or DM are often undertreated for known causative agents and exacerbators of ASCVD. Herein, we propose an approach to assess and manage the heightened risk of ASCVD events in patients with LE or DM. Our approach is modeled in large part on established approaches to patients with diabetes mellitus or stage 3 or 4 chronic kidney disease, which are well-studied conditions that also show heightened risk for ASCVD events and have been explicitly incorporated into standard clinical guidelines for ASCVD. Based on the available evidence, we conclude that patients with LE or DM require earlier and more aggressive screening and management of ASCVD. We suggest that physicians consider implementing multipliers of conventional risk calculators to trigger earlier initiation of lifestyle modifications and medical therapies in primary prevention of ASCVD events, employ vascular imaging to quantify the burden of subclinical plaques, and treat to lower lipid targets using statins and newer therapies, such as PCSK9 inhibitors, that decrease ASCVD events in nonautoimmune cohorts. More clinical vigilance is needed regarding surveillance, prevention, risk modification, and treatment of dyslipidemias, hypertension, and smoking in patients with LE or DM. All of these goals are achievable.
- 9 September 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (5) , 560-575
Open AccessAssessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis
For patients with lupus erythematosus (LE) or dermatomyositis (DM), there is an urgent need to address a heightened risk of clinical events, chiefly heart attacks and strokes, caused by atherosclerotic cardiovascular disease (ASCVD). Patients with LE or DM frequently exhibit high levels of conventional risk factors for ASCVD events, particularly dyslipoproteinemia and hypertension; an amplified burden of atherosclerotic plaques; and increased age- and sex-adjusted rates of ASCVD events compared with the general population. The rate of ASCVD events exceeds what would be expected from conventional risk factors, suggesting that disease-specific autoimmune processes exacerbate specific, known pathogenic steps in atherosclerosis. Importantly, despite their heightened risk, patients with LE or DM are often undertreated for known causative agents and exacerbators of ASCVD. Herein, we propose an approach to assess and manage the heightened risk of ASCVD events in patients with LE or DM. Our approach is modeled in large part on established approaches to patients with diabetes mellitus or stage 3 or 4 chronic kidney disease, which are well-studied conditions that also show heightened risk for ASCVD events and have been explicitly incorporated into standard clinical guidelines for ASCVD. Based on the available evidence, we conclude that patients with LE or DM require earlier and more aggressive screening and management of ASCVD. We suggest that physicians consider implementing multipliers of conventional risk calculators to trigger earlier initiation of lifestyle modifications and medical therapies in primary prevention of ASCVD events, employ vascular imaging to quantify the burden of subclinical plaques, and treat to lower lipid targets using statins and newer therapies, such as PCSK9 inhibitors, that decrease ASCVD events in nonautoimmune cohorts. More clinical vigilance is needed regarding surveillance, prevention, risk modification, and treatment of dyslipidemias, hypertension, and smoking in patients with LE or DM. All of these goals are achievable.